Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Conclusion: HyperCD-based regimens yielded relatively high response rates in MM patients with renal insufficiency, including renal failure. Several patients discontinued dialysis, with improvement in renal function also seen in non-dialysis patients. While TRM was low, hematologic, infectious, and cardiac toxicities were common. The majority of patients were able to successfully bridge to other therapy. HyperCD-based regimens may thus be a potential alternative to platinum based therapies in myeloma patients requiring intensive infusional chemotherapy.DisclosuresShah: Nekktar: Consultancy; Teneobio: Consultancy; Amgen: Consultancy; Sutro Biopharma: Research Funding; Janssen: Research Funding; Nkarta: Consultancy; Indapta Therapeutics: Equity Ownership; Takeda: Consultancy; Celgene: Research Funding; Indapta Therapeutics: Consultancy; Bluebird: Research Funding; University of California San Francisco: Employment; Kite: Consultancy; Sanofi: Consultancy; Bristol Myers Squibb: Consultancy. Wong: Janssen: Research Funding; Roche: Research Funding. Martin: Sanofi: Research Funding; Amgen: Research Funding; Roche: Consultancy. Wolf: Amgen: Consultancy; Celgene: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Novartis: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Galligan, D., Narayan, R., Kim, S., Lazar, A., Tan, M., Fong, R., Lo, M., Shah, N., Arora, S., Wong, S. W., Martin, T. G., Wolf, J. L. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster II Source Type: research